# US 2021/0171503 A1 · Glycolate oxidase inhibitors and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0171503 A1
- Document ID: US20210171503A1
- Status: Published application
- Kind: A1
- Application number: 16/958,348
- Filed: 2018-12-28
- Published: 2021-06-10
- Earliest claimed: 2017-12-29
- Assignees: Orfan Biotech Inc.
- Applicants: Orfan Biotech Inc.
- Inventors: Hans MAAG; Miguel Xavier Fernandes
- Web page: https://patentgrep.com/patent/US20210171503A1

## CPC

- C07D 403/12: linked by a chain containing hetero atoms as chain links
- A61P 13/12: of the kidneys
- C07D 231/18: One oxygen or sulfur atom
- C07D 231/38: Nitrogen atoms (nitro radicals C07D231/16)
- C07D 237/18: Sulfur atoms
- C07D 237/24: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D 261/18: Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
- C07D 275/03: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D 285/06: 1,2,3-Thiadiazoles; Hydrogenated 1,2,3-thiadiazoles
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 413/12: linked by a chain containing hetero atoms as chain links
- C07D 417/12: linked by a chain containing hetero atoms as chain links
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides pyrazoles, isoxazoles, isothiazoles, thiadiazoles, and pyridazines according to Formula I as described herein, and pharmaceutically acceptable salts thereof. Pharmaceutical compositions and methods for treating primary hyperoxaluria, type I (PH) and kidney stones are also described.

## Claims

### Claim 1

A compound according to Formula I:
or a pharmaceutically acceptable salt or C1-6 alkyl ester thereof,
wherein:
ring A is selected from the group consisting of 1,2,3-thiadiazol-4,5-diyl, (5-methyl)-1H-pyrazol-3,4-diyl, (5-methyl)-isoxazol-3,4-diyl, (5-methyl)-isothiazol-3,4-diyl, and pyridazin-3,4-diyl;
subscript n is 1, 2, 3, or 0;
subscript m is 0, 1, or 2;
W is selected from the group consisting of —NR3—, —C(R3)2—, —O—, —S—, —S(O)—, and —S(O)2—;
each Y, if present, is independently selected from the group consisting of —O— and —C(R4)2—;
R1 is selected from the group consisting of halo, cyano, 5- to 6-membered heteroaryl, and -L-(C6-10 aryl), wherein aryl is optionally substituted with R1a;
R2 is selected from the group consisting of H and C1-6 alkyl;
each R3 is independently selected from the group consisting of H, C1-6 alkyl, and C7-16 arylalkyl, wherein aryl in arylalkyl is optionally substituted with R3a;
each R4 is independently selected from the group consisting of H, C1-6 alkyl, and C7-16 arylalkyl, wherein aryl in arylalkyl is optionally substituted with R4a; or
two R4 are taken together to form C2-6 alkenyl;
R1a is independently selected from the group consisting of halo, cyano, -M-(8- to 12-membered heterocyclyl), -M-(5- to 6-membered heteroaryl), -M-(C3-8 cycloalkyl), and -M-(C6-10 aryl), wherein heterocyclyl, heteroaryl, cycloalkyl, and aryl are optionally substituted with R1b;
R3a is independently selected from the group consisting of halo, cyano, C1-6 alkyl, C1-6 alkoxy, -M-(8- to 12-membered heterocyclyl), -M-(5- to 6-membered heteroaryl), -M-(C3-8 cycloalkyl), and -M-(C6-10 aryl), wherein heterocyclyl, heteroaryl, cycloalkyl, and aryl are optionally substituted with R3b;
R4a is independently selected from the group consisting of halo, cyano, -Q-(8- to 12-membered heterocyclyl), -Q-(5- to 6-membered heteroaryl), -Q-(C3-8 cycloalkyl), and -Q-(C6-10 aryl), wherein heterocyclyl, heteroaryl, cycloalkyl, and aryl are optionally substituted with R4b;
each of R1b, R3b, and R4b is independently selected from the group consisting of halo and cyano;
L, M, and Q are independently selected from the group consisting of a bond, —O—, C1-6 alkylene, C2-6 alkenylene, C2-6 alkynylene, and 2- to 6-membered heteroalkylene; and
each heterocyclyl is optionally and independently substituted with one or more amine protecting groups;
provided that if ring A is 1,2,3-thiadiazol-4,5-diyl, W is —NR3—, R3 is butyl, subscript m is 1, Y is —CHR4—, R4 is H, and subscript n is 1, then R1 is other than 4-(2H-tetrazol-5-yl)phenyl;
provided that if ring A is 1,2,3-thiadiazol-4,5-diyl, W is —CH2— or —NH—, and subscript m is 0, then subscript n is 1, 2, or 3;
provided that if ring A is 1,2,3-thiadiazol-4,5-diyl, W is —S—, subscript m is 1, and Y is —CH2—, then subscript n is 1, 2, or 3;
provided that if ring A is 1,2,3-thiadiazol-4,5-diyl, W is S, subscript n is 1, and subscript m is 0, then R1 is other than 4-chloro;
provided that if ring A is (5-methyl)-isoxazol-3,4-diyl, W is —CH2—, subscript n is 1, and subscript m is 1, then Y is 0;
provided that if ring A is (5-methyl)-isoxazol-3,4-diyl, W is —CH2—, and subscript m is 0, then subscript n is 1, 2, or 3;
provided that if ring A is (5-methyl)-isoxazol-3,4-diyl, W is —CH2—, subscript n is 1, and subscript m is 0, then R1 is other than 3-bromo, 4-bromo, 3-chloro, 4-chloro, 3-fluoro, and 4-fluoro;
provided that if ring A is (5-methyl)-1H-pyrazol-3,4-diyl, W is —NR3—, R3 is H or C1-6 alkyl, and subscript m is 0, then subscript n is 1, 2, or 3;
provided that if ring A is (5-methyl)-1H-pyrazol-3,4-diyl, W is —NR3—, R3 is H or C1-6 alkyl, subscript m is 1, and Y is —CH2—, then subscript n is 1, 2, or 3;
provided that if ring A is (5-methyl)-isoxazol-3,4-diyl, W is —NH—, subscript n is 1, and subscript m is 0, then R1 is other than 3-cyano, 4-cyano, 3-bromo, 4-bromo, 3-chloro, 4-chloro, 3, fluoro, and 4-fluoro;
provided that if ring A is (5-methyl)-1H-pyrazol-3,4-diyl, W is —CH2—, subscript n is 1, and subscript m is 1, then Y is 0;
provided that if ring A is (5-methyl)-1H-pyrazol-3,4-diyl, W is —CH2—, and subscript m is 0, then subscript n is 1, 2, or 3;
provided that if ring A is (5-methyl)-1H-pyrazol-3,4-diyl, W is —CH2—, subscript n is 1, and subscript m is 0, then R1 is other than 3-cyano, 4-cyano, 4-bromo, 3-chloro, 4-chloro, 3-fluoro, 4-fluoro, 3-pyridin-3-yl, 3-pyridin-4-yl, 3-(4-cyanophenyl), 3-(4-fluorophenyl), 4-(4-fluorophenyl), 3-phenoxyphenyl, and 4-phenoxyphenyl;
provided that if ring A is pyridazin-3,4-diyl, W is —NR3—, Y is —CHR4—, R3 is propyl, R4 is H, subscript n is 1, and subscript m is 1, then R1 is other than 4-(2H-tetrazol-5-yl)phenyl.

### Claim 2 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, according to a formula selected from the group consisting of Formula II, Formula III, and Formula IV:
wherein Z is selected from the group consisting of NH, O, and S.

### Claim 3

(canceled)

### Claim 4 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, according to a formula selected from the group consisting of Formula IIIa, Formula IIIb, and Formula IIIc:

### Claim at position 5

5-7. (canceled)

### Claim 8 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein W is —NR3—.

### Claim at position 7

9-13. (canceled)

### Claim 14 (depends on 8)

The compound of claim 8, or a pharmaceutically acceptable salt thereof, wherein:
subscript n is 1;
R1 is selected from the group consisting of heteroaryl and -L-(C6-10 aryl), wherein aryl is substituted with R1a;
R1a is selected from the group consisting of halo, cyano, and -M-heterocyclyl, heterocyclyl is optionally substituted with one or more amine protecting groups,
L is selected from the group consisting of a bond, —O—, and C1-6 alkylene, and
M is 2- to 6-membered heteroalkylene.

### Claim at position 9

15-17. (canceled)

### Claim 18 (depends on 8)

The compound of claim 8, or a pharmaceutically acceptable salt thereof, wherein:
subscript n is 1
R1 is halo;
R3 is C7-16 arylalkyl substituted with R3a; and
R3a is halo.

### Claim at position 11

19-20. (canceled)

### Claim 21 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein each Y is independently selected from the group consisting of —O— and —CHR4—.

### Claim 22 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, R3a is independently selected from the group consisting of halo, cyano, -M-(8- to 12-membered heterocyclyl), -M-(5- to 6-membered heteroaryl), -M-(C3-8 cycloalkyl), and -M-(C6-10 aryl), wherein heterocyclyl, heteroaryl, cycloalkyl, and aryl are optionally substituted with R3b.

### Claim 23 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein L, M, and Q are independently selected from the group consisting of a bond, —O—, C1-6 alkylene, and 2- to 6-membered heteroalkylene.

### Claim 24 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein:
W is —NR3—;
Y is —CHR4—;
subscript n is 0 or 1;
subscript m is 0, 1, or 2;
R1 is halo or -L-(C6-10 aryl), wherein aryl is optionally substituted with R1a;
R3 is C7-16 arylalkyl, wherein aryl in arylalkyl is substituted with R3a;
R4 is H;
R3a is halo or -M-(C6-10 aryl), wherein aryl is optionally substituted with R3b;
each of R1b and R3b is independently selected from the group consisting of halo and cyano;
L and M are independently selected from the group consisting of a bond, —O—, C1-6 alkylene, and 2- to 6-membered heteroalkylene; and
each heterocyclyl is optionally and independently substituted with one or more amine protecting groups.

### Claim 25

(canceled)

### Claim 26 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein W is —CHR3—.

### Claim at position 18

27-31. (canceled)

### Claim 32 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein W is selected from the group consisting of —S—, —S(O)—, and —S(O)2—.

### Claim at position 20

33-42. (canceled)

### Claim 43 (depends on 1)

The compound of claim 1, which is selected from the group consisting of
and pharmaceutically acceptable salts thereof.

### Claim 44 (depends on 1)

The compound of claim 1, which is selected from the group consisting of
and pharmaceutically acceptable salts thereof.

### Claim 45 (depends on 1)

The compound of claim 1, which is selected from the group consisting of
and pharmaceutically acceptable salts thereof.

### Claim 46 (depends on 1)

The compound of claim 1, which is selected from the group consisting of
and pharmaceutically acceptable salts thereof.

### Claim 47 (depends on 1)

The compound of claim 1, which is selected from the group consisting of
and pharmaceutically acceptable salts thereof.

### Claim 48 (depends on 1)

A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable excipient.

### Claim 49

A method for treating primary hyperoxaluria, type I (PH1) comprising administering to a subject in need thereof a therapeutically effective amount of a compound according to Formula I:
or a pharmaceutically acceptable salt thereof, wherein:
ring A is selected from the group consisting of 1,2,3-thiadiazol-4,5-diyl, (5-methyl)-1H-pyrazol-3,4-diyl, (5-methyl)-isoxazol-3,4-diyl, (5-methyl)-isothiazol-3,4-diyl, and pyridazin-3,4-diyl;
subscript n is 0, 1, 2, or 3;
subscript m is 0, 1, or 2;
W is selected from the group consisting of —NR3—, —C(R3)2—, —O—, —S—, —S(O)—, and —S(O)2—;
each Y is independently selected from the group consisting of —O— and —C(R4)2—;
R1 is selected from the group consisting of halo, cyano, 5- to 6-membered heteroaryl, and -L-(C6-10 aryl), wherein aryl is optionally substituted with R1a;
R2 is selected from the group consisting of H and C1-6 alkyl;
each R3 is independently selected from the group consisting of H, C1-6 alkyl, and C7-16 arylalkyl, wherein aryl in arylalkyl is optionally substituted with R3a;
each R4 is independently selected from the group consisting of H, C1-6 alkyl, and C7-16 arylalkyl, wherein aryl in arylalkyl is optionally substituted with R4a; or
two R4 are taken together to form C2-6 alkenyl;
R1a is independently selected from the group consisting of halo, cyano, -M-(8- to 12-membered heterocyclyl), -M-(5- to 6-membered heteroaryl), -M-(C3-8 cycloalkyl), and -M-(C6-10 aryl), wherein heterocyclyl, heteroaryl, cycloalkyl, and aryl are optionally substituted with R1b;
R3a is independently selected from the group consisting of halo, cyano, C1-6 alkyl, C1-6 alkoxy, -M-(8- to 12-membered heterocyclyl), -M-(5- to 6-membered heteroaryl), -M-(C3-8 cycloalkyl), and -M-(C6-10 aryl), wherein heterocyclyl, heteroaryl, cycloalkyl, and aryl are optionally substituted with R3b;
R4a is independently selected from the group consisting of halo, cyano, -Q-(8- to 12-membered heterocyclyl), -Q-(5- to 6-membered heteroaryl), -Q-(C3-8 cycloalkyl), and -Q-(C6-10 aryl), wherein heterocyclyl, heteroaryl, cycloalkyl, and aryl are optionally substituted with R4b;
each of R1, R3b, and R4b is independently selected from the group consisting of halo and cyano;
L, M, and Q are independently selected from the group consisting of a bond, —O—, 37 C1-6 alkylene, C2-6 alkenylene, C2-6 alkynylene, and 2- to 6-membered heteroalkylene; and
each heterocyclyl is optionally and independently substituted with one or more amine protecting groups;
provided that if ring A is 1,2,3-thiadiazol-4,5-diyl, W is S, subscript n is 1, and subscript m is 0, then R1 is other than 4-chloro;
thereby treating the PH1.

### Claim 50

A method for treating kidney stones comprising administering to a subject in need thereof a therapeutically effective amount of a compound according to Formula I:
or a pharmaceutically acceptable salt thereof, wherein:
ring A is selected from the group consisting of 1,2,3-thiadiazol-4,5-diyl, (5-methyl)-1H-pyrazol-3,4-diyl, (5-methyl)-isoxazol-3,4-diyl, (5-methyl)-isothiazol-3,4-diyl, and pyridazin-3,4-diyl;
subscript n is 0, 1, 2, or 3;
subscript m is 0, 1, or 2;
W is selected from the group consisting of —NR3—, —C(R3)2—, —O—, —S—, —S(O)—, and —S(O)2—;
each Y is independently selected from the group consisting of —O— and —C(R4)2—;
R1 is selected from the group consisting of halo, cyano, 5- to 6-membered heteroaryl, and -L-(C6-10 aryl), wherein aryl is optionally substituted with R1a;
R2 is selected from the group consisting of H and C1-6 alkyl;
each R3 is independently selected from the group consisting of H, C1-6 alkyl, and C7-16 arylalkyl, wherein aryl in arylalkyl is optionally substituted with R3a;
each R4 is independently selected from the group consisting of H, C1-6 alkyl, and C7-16 arylalkyl, wherein aryl in arylalkyl is optionally substituted with R4a; or
two R4 are taken together to form C2-6 alkenyl;
R1a is independently selected from the group consisting of halo, cyano, -M-(8- to 12-membered heterocyclyl), -M-(5- to 6-membered heteroaryl), -M-(C3-8 cycloalkyl), and -M-(C6-10 aryl), wherein heterocyclyl, heteroaryl, cycloalkyl, and aryl are optionally substituted with R1b;
R3a is independently selected from the group consisting of halo, cyano, C1-6 alkyl, C1-6 alkoxy, -M-(8- to 12-membered heterocyclyl), -M-(5- to 6-membered heteroaryl), -M-(C3-8 cycloalkyl), and -M-(C6-10 aryl), wherein heterocyclyl, heteroaryl, cycloalkyl, and aryl are optionally substituted with R3b;
R4a is independently selected from the group consisting of halo, cyano, -Q-(8- to 12-membered heterocyclyl), -Q-(5- to 6-membered heteroaryl), -Q-(C3-8 cycloalkyl), and -Q-(C6-10 aryl), wherein heterocyclyl, heteroaryl, cycloalkyl, and aryl are optionally substituted with R4b;
each of R1b, R3b, and R4b is independently selected from the group consisting of halo and cyano;
L, M, and Q are independently selected from the group consisting of a bond, —O—, 37 C1-6 alkylene, C2-6 alkenylene, C2-6 alkynylene, and 2- to 6-membered heteroalkylene; and
each heterocyclyl is optionally and independently substituted with one or more amine protecting groups;
provided that if ring A is 1,2,3-thiadiazol-4,5-diyl, W is S, subscript n is 1, and subscript m is 0, then R1 is other than 4-chloro;
thereby treating the kidney stones.

### Claim at position 29

51-54. (canceled)
